“…We hypothesized that co-exposure of LPS and ZymA with H-ASD The co-exposure induced a significant increase in total cell number and production of MCP-1 and MCP-3 and tended to increase Kitaura et al, 1996;Ponath et al, 1996), and MCP-1 and IL-17 facilitate the recruitment of monocytes (Matsushima, Larsen, DuBois, & Oppenheim, 1989) and neutrophils (Laan et al, 1999), respectively, during inflammation. We used the same doses of LPS (1 ng) and ZymA (20 ng) as in previous studies (Ren et al, 2014;Sadakane et al, 2016). The levels of eotaxin, MCP-3 and MCP-1 in BALF were markedly increased in OVA + ZymA + H-ASD treatment compared with the control, ZymA only, OVA-only or OVA + ZymA treatment (IL-17 was not measured) (Sadakane et al, 2016).…”